Blockchain Registration Transaction Record

Theriva Biologics Receives FDA Fast Track Designation for VCN-01 in Pancreatic Cancer Treatment

Theriva Biologics receives FDA Fast Track Designation for VCN-01, a promising treatment for pancreatic cancer. This milestone underscores the potential to improve patient outcomes and reduce mortality. Learn more about the company's innovative approach to cancer treatment.

The FDA's Fast Track Designation for VCN-01 reflects the urgent need for new treatment options for pancreatic cancer, a leading cause of cancer death globally. This milestone underscores the potential of VCN-01 to improve patient outcomes and reduce mortality. As incidences of pancreatic cancer continue to rise, Theriva Biologics' focus on innovative cancer therapies could have a significant impact on the industry and patient care.